Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Enzon Files IND for Cancer Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Enzon Files IND for Cancer Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Enzon Pharmaceuticals, Inc. has submitted an IND to the FDA for its HIF-1alpha (hypoxia-inducible factor 1alpha) antagonist, a highly visible, validated target in many cancer types, including solid tumors.

“2006 was a very exciting year for Enzon, as we began to build an innovative oncology pipeline, said Jeffrey Buchalter, chairman and chief executive officer, Enzon. The filing of HIF-1alpha, our fourth IND submission in 2006, demonstrates our strong commitment to delivering on our promises and developing a differentiated cancer portfolio.”

The target HIF-1alpha functions as a key regulator of a large number of genes important in cancer biology, such as angiogenesis, cell proliferation, apoptosis and cell invasion. HIF-1alpha protein reaches high intracellular concentrations in a variety of cancers and is associated with poor prognosis and resistance to therapy. Drugs targeting HIF-1alpha have the potential to target multiple cancer processes.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters